![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: DUOX1 |
Gene summary for DUOX1 |
![]() |
Gene information | Species | Human | Gene symbol | DUOX1 | Gene ID | 53905 |
Gene name | dual oxidase 1 | |
Gene Alias | LNOX1 | |
Cytomap | 15q21.1 | |
Gene Type | protein-coding | GO ID | GO:0006575 | UniProtAcc | Q9NRD9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
53905 | DUOX1 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 3.89e-15 | 7.11e-01 | -0.2116 |
53905 | DUOX1 | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 5.74e-03 | 4.75e-01 | -0.1941 |
53905 | DUOX1 | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 1.99e-05 | 5.79e-01 | -0.2107 |
53905 | DUOX1 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 1.80e-09 | 6.56e-01 | -0.2119 |
53905 | DUOX1 | C04 | Human | Oral cavity | OSCC | 5.46e-07 | 3.18e-01 | 0.2633 |
53905 | DUOX1 | C21 | Human | Oral cavity | OSCC | 1.41e-21 | 4.88e-01 | 0.2678 |
53905 | DUOX1 | C30 | Human | Oral cavity | OSCC | 1.16e-18 | 6.72e-01 | 0.3055 |
53905 | DUOX1 | C38 | Human | Oral cavity | OSCC | 2.68e-12 | 7.77e-01 | 0.172 |
53905 | DUOX1 | C43 | Human | Oral cavity | OSCC | 1.09e-08 | 2.54e-01 | 0.1704 |
53905 | DUOX1 | C46 | Human | Oral cavity | OSCC | 2.33e-21 | 4.63e-01 | 0.1673 |
53905 | DUOX1 | C51 | Human | Oral cavity | OSCC | 1.08e-17 | 6.35e-01 | 0.2674 |
53905 | DUOX1 | C57 | Human | Oral cavity | OSCC | 5.94e-08 | 3.32e-01 | 0.1679 |
53905 | DUOX1 | C06 | Human | Oral cavity | OSCC | 2.92e-05 | 5.20e-01 | 0.2699 |
53905 | DUOX1 | C08 | Human | Oral cavity | OSCC | 2.18e-03 | 1.72e-01 | 0.1919 |
53905 | DUOX1 | C09 | Human | Oral cavity | OSCC | 2.55e-15 | 4.27e-01 | 0.1431 |
53905 | DUOX1 | LN22 | Human | Oral cavity | OSCC | 2.05e-07 | 9.05e-01 | 0.1733 |
53905 | DUOX1 | LN46 | Human | Oral cavity | OSCC | 4.35e-13 | 4.24e-01 | 0.1666 |
53905 | DUOX1 | LP15 | Human | Oral cavity | LP | 1.56e-04 | 7.12e-01 | 0.2174 |
53905 | DUOX1 | SYSMH1 | Human | Oral cavity | OSCC | 6.68e-07 | 2.88e-01 | 0.1127 |
53905 | DUOX1 | SYSMH2 | Human | Oral cavity | OSCC | 1.98e-07 | 3.58e-01 | 0.2326 |
Page: 1 2 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000697913 | Lung | AIS | response to oxidative stress | 75/1849 | 446/18723 | 2.97e-06 | 1.60e-04 | 75 |
GO:004206013 | Lung | AIS | wound healing | 71/1849 | 422/18723 | 5.32e-06 | 2.52e-04 | 71 |
GO:005159113 | Lung | AIS | response to cAMP | 21/1849 | 93/18723 | 2.35e-04 | 4.68e-03 | 21 |
GO:00466838 | Lung | AIS | response to organophosphorus | 24/1849 | 131/18723 | 2.14e-03 | 2.30e-02 | 24 |
GO:00140748 | Lung | AIS | response to purine-containing compound | 25/1849 | 148/18723 | 5.34e-03 | 4.56e-02 | 25 |
GO:000697920 | Oral cavity | OSCC | response to oxidative stress | 273/7305 | 446/18723 | 8.35e-22 | 1.65e-19 | 273 |
GO:004206020 | Oral cavity | OSCC | wound healing | 237/7305 | 422/18723 | 4.51e-13 | 2.18e-11 | 237 |
GO:000963618 | Oral cavity | OSCC | response to toxic substance | 137/7305 | 262/18723 | 7.94e-06 | 8.52e-05 | 137 |
GO:007259316 | Oral cavity | OSCC | reactive oxygen species metabolic process | 122/7305 | 239/18723 | 9.73e-05 | 7.34e-04 | 122 |
GO:00192214 | Oral cavity | OSCC | cytokine-mediated signaling pathway | 222/7305 | 472/18723 | 2.02e-04 | 1.35e-03 | 222 |
GO:190303418 | Oral cavity | OSCC | regulation of response to wounding | 87/7305 | 167/18723 | 3.91e-04 | 2.38e-03 | 87 |
GO:199074818 | Oral cavity | OSCC | cellular detoxification | 63/7305 | 116/18723 | 5.80e-04 | 3.31e-03 | 63 |
GO:009886918 | Oral cavity | OSCC | cellular oxidant detoxification | 55/7305 | 101/18723 | 1.16e-03 | 5.89e-03 | 55 |
GO:009723718 | Oral cavity | OSCC | cellular response to toxic substance | 65/7305 | 124/18723 | 1.63e-03 | 7.74e-03 | 65 |
GO:006104116 | Oral cavity | OSCC | regulation of wound healing | 69/7305 | 134/18723 | 2.19e-03 | 9.95e-03 | 69 |
GO:190303615 | Oral cavity | OSCC | positive regulation of response to wounding | 40/7305 | 72/18723 | 3.21e-03 | 1.38e-02 | 40 |
GO:00065756 | Oral cavity | OSCC | cellular modified amino acid metabolic process | 91/7305 | 188/18723 | 5.33e-03 | 2.07e-02 | 91 |
GO:009875418 | Oral cavity | OSCC | detoxification | 75/7305 | 152/18723 | 5.99e-03 | 2.28e-02 | 75 |
GO:00903039 | Oral cavity | OSCC | positive regulation of wound healing | 33/7305 | 59/18723 | 6.17e-03 | 2.33e-02 | 33 |
GO:0006979110 | Oral cavity | LP | response to oxidative stress | 181/4623 | 446/18723 | 5.74e-14 | 6.10e-12 | 181 |
Page: 1 2 3 4 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DUOX1 | SNV | Missense_Mutation | novel | c.2252N>A | p.Met751Lys | p.M751K | Q9NRD9 | protein_coding | tolerated(0.09) | benign(0.003) | TCGA-DD-AADD-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
DUOX1 | SNV | Missense_Mutation | novel | c.4231N>G | p.Gln1411Glu | p.Q1411E | Q9NRD9 | protein_coding | deleterious(0.03) | benign(0.439) | TCGA-05-4397-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
DUOX1 | SNV | Missense_Mutation | c.3085N>A | p.Gln1029Lys | p.Q1029K | Q9NRD9 | protein_coding | tolerated(0.12) | benign(0.14) | TCGA-44-2656-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
DUOX1 | SNV | Missense_Mutation | novel | c.1760A>G | p.Tyr587Cys | p.Y587C | Q9NRD9 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-44-8117-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DUOX1 | SNV | Missense_Mutation | novel | c.3877N>A | p.Gln1293Lys | p.Q1293K | Q9NRD9 | protein_coding | tolerated(0.92) | benign(0.1) | TCGA-NJ-A4YQ-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DUOX1 | SNV | Missense_Mutation | novel | c.2718N>C | p.Glu906Asp | p.E906D | Q9NRD9 | protein_coding | tolerated(0.14) | benign(0.067) | TCGA-21-1079-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
DUOX1 | SNV | Missense_Mutation | novel | c.2950N>A | p.Gln984Lys | p.Q984K | Q9NRD9 | protein_coding | tolerated(0.87) | benign(0.02) | TCGA-22-1016-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
DUOX1 | SNV | Missense_Mutation | novel | c.569N>T | p.Arg190Leu | p.R190L | Q9NRD9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-22-5483-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | taxol | PD |
DUOX1 | SNV | Missense_Mutation | c.4427A>G | p.Gln1476Arg | p.Q1476R | Q9NRD9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-43-5668-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Other, specify in notesMAGE3-AS15-NSC-003 | clinical | PD | |
DUOX1 | SNV | Missense_Mutation | c.59N>T | p.Gly20Val | p.G20V | Q9NRD9 | protein_coding | tolerated(0.06) | benign(0.037) | TCGA-43-6770-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Vaccine | recprame+as15 | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |